At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 331 enrolled
Drug / intervention
Dietressa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of New Dosage Schedule for Dietressa Drug in Treatment of Obese Patients
In Brief
A Phase 3 clinical trial evaluating Dietressa and Placebo for Obesity. Completed, enrolled 331 participants across 17 sites.
Detailed Summary
* To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients (BMI 35,0-39,9 kg/m2). * To assess clinical efficacy of Dietressa in the dose of 6 tablets daily after 24 weeks of therapy in reducing body weight in obese patients (BMI 35,0-39,9 kg/m2).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesRussia
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedApr 2012
Primary CompletionJun 2013
TodayJul 2026
First PostedApr 4, 2012
Enrollment StartDec 1, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.2 years ago
Interventions
Dietressadrug
Oral administration.
Placebodrug
Oral administration.